The USITC has issued a 497 page report on the WTO negotiations over TRIPS and COVID. https://www.usitc.gov/publications/332/pub5469.pdf The USITC release states: The U.S. International Trade Commission (USITC) today released a report about COVID-19 diagnostics and therapeutics and certain flexibilities under… Continue Reading →
On October 12, 2023, Knowledge Ecology International (KEI) filed comments regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered T Cell Therapies for the Treatment of Cancer” by the National Institutes of Health (NIH) to… Continue Reading →
Summary of September 28, 2023 comments to the TRIPS Council On Paragraph 8 Of The Ministerial Decision On The TRIPS Agreement James Love Knowledge Ecology International (KEI) The June 17, 2022 decision on the TRIPS Agreement and COVID-19 vaccines was… Continue Reading →
Knowledge Ecology International (KEI) invites WIPO delegates attending the 35th session of the Standing Committee on the Law of Patents (SCP) to a side event on Tuesday, 17 October 2023. James Love’s slides can be found here: https://www.keionline.org/wp-content/uploads/52.227-1-wipo-17oct2023.pdf Title: US… Continue Reading →
These are the slides that were used in a KEI-People’s Vaccine Alliance webinar on delinking R&D financing from temporary monopolies. KEI-PVA-webinar-Delinking-rnd-5oct2023
On October 2, 2023, Knowledge Ecology International submitted written comments to the Centers for Medicare & Medicaid Services (CMS) in conjunction with the Medicare Price Negotiation public consultation process. CMS is hosting a series of patient-focused listening sessions this fall,… Continue Reading →
Mismatch between the cost to perform pediatric extension trials and the cost to the public of the six month extension of the drug monopoly KEI Briefing Note 2023:2 September 20, 2023 James Love, Manon Ress and Claire Cassedy KEI-BN-2023-2
Today, Knowledge Ecology International (KEI) submitted a letter to the Commissioner of the Food and Drug Administration (FDA) regarding the mismatch between the cost to perform pediatric extension trials and the cost to the public of the six month extension… Continue Reading →
On 1 September 2023, Csaba Kőrösi, President of the 77th United Nations General Assembly, circulated three draft texts of political declarations related to the following processes: High-level meeting on pandemic prevention, preparedness and response(resolution77/275) High-level meeting on universal health coverage… Continue Reading →
In May 2023, the World Health Organization (WHO) published the global vaccine market report. Underpinning this technical report on vaccine market dynamics was a strong push by WHO’s Director-General, Tedros Adhanom Ghebreyesus, for increased transparency and equity; transparency is mentioned… Continue Reading →